A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company focused on developing first-in-class logic-gated cell therapies to selectively target tumor cells while protecting healthy cells, has announced that six of its abstracts have been accepted for presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), scheduled for November 8-10, 2024, in Houston.
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage company focused on innovative logic-gated cell therapies that selectively target tumor cells while protecting normal cells, has announced the acceptance of six abstracts for presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place from November 8-10, 2024, in Houston.
The company will deliver an oral presentation on its ongoing efforts to enhance patient diversity in the BASECAMP-1 prescreening trial. Additional posters will provide safety and biomarker data from the EVEREST-1 trial, updates on the EVEREST-2 clinical trial, and modifications aimed at increasing the potency and preserving the selectivity of Tmod™-based cell therapies.
Oral Presentation Details:
- Title: “BASECAMP-1 is an efficient pre-screening study that identifies patients with HLA LOH and provides mutational, RNA-Seq, and microbiome data for precision logic-gated CAR T therapeutic trials”
- Session Title: Cellular Therapies – Financial Toxicities, Access to Care
- Date/Time: Saturday, Nov. 9, 5:15-6:35 p.m. CDT
- Location: George R. Brown Convention Center – Level 3 – Grand Ballroom B
- Final Abstract Number: 589
- Presenting Author: Julian Molina, M.D., Ph.D., Mayo Clinic
Poster Presentation Details:
| Abstract Title | Author | Abstract Number | Presentation Date | Location |
|---|---|---|---|---|
| EVEREST-1: Initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH | Patrick Grierson | 588 | Saturday, November 9, 9 a.m.-8:30 p.m. | Exhibit Halls A B, George R. Brown Convention Center |
| BASECAMP-1: Identifying patients with HLA LOH for precision CAR T therapeutic trials | Julian Molina | 589 | Friday, November 8, 9 a.m.-7 p.m. | |
| EVEREST-2: A seamless phase 1/2 study of A2B694 in patients with solid tumors with HLA-A*02 loss of heterozygosity | Julian Molina | 627 | ||
| Tmod NOT gate: Enhancing potency while maintaining selectivity | Jingli Zhang | 341 | Saturday, November 9, 9 a.m.-8:30 p.m. | |
| Optimizing logic gate potency and selectivity | Sara Martire | 292 | Saturday, November 9, 9 a.m.-8:30 p.m. | |
| Signal 1 boosters for Tmod: Addressing challenges in cell therapy for solid tumors | Julie Oh | 302 | Saturday, November 9, 9 a.m.-8:30 p.m. |
About EVEREST-1
EVEREST-1 (NCT05736731) is a seamless Phase 1/2 study evaluating A2B530, an autologous logic-gated cell therapy developed from the A2 Bio proprietary Tmod™ platform. This platform employs a dual-receptor design to selectively target tumor cells while protecting normal cells. A2B530 targets carcinoembryonic antigen (CEA) with an HLA-A*02 blocker, recruiting participants with non-small cell lung, colorectal, and pancreatic cancers.
About EVEREST-2
EVEREST-2 (NCT06051695) is another seamless Phase 1/2 study for A2B694, an investigational cell therapy targeting mesothelin (MSLN) while using HLA-A*02 as a blocker. This study also seeks participants with various solid tumors, including non-small cell lung, colorectal, pancreatic, ovarian, and mesothelioma cancers.
About BASECAMP-1
BASECAMP-1 (NCT04981119) is a prescreening study aimed at identifying patients for potential A2 Bio clinical trials. It optimizes treatment outcomes by banking patients’ immune cells at their healthiest state. The study uses next-generation sequencing to identify HLA-A*02 loss and collects T cells for future Tmod™ CAR T cell therapy. It is currently enrolling participants with non-small cell lung, colorectal, pancreatic, ovarian, and mesothelioma cancers.
About the Tmod™ Platform
The Tmod™ platform developed by A2 Bio utilizes a precision-targeting system with an activator and blocker to direct immune cell activity precisely at tumors, distinguishing them from normal tissues. This innovative approach enhances the effectiveness of T cell targeting.
About A2 Bio
A2 Biotherapeutics, Inc. (A2 Bio) is a clinical-stage biotech company focused on developing first-in-class logic-gated cell therapies to meet the high unmet need in cancer treatment, addressing the challenge of differentiating between tumor and normal cells.
